The approval gives physicians an alternative to uncoated balloons and Boston Scientific’s paclitaxel-coated device.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

On Aug. 26, 2026, a cyberattack halted order processing and shipping at the medical device maker, leaving investors uncertain about the speed of recovery and near-term shipment delays.
Boston Scientific recently reported its second-quarter 2026 results, showing sales of US$5,442 million and net income of US$907 million, alongside issuing a recall of its Rapid Refill Continuous Injection System and initiating a multi-year global restructuring plan aimed at cost efficiencies. While the company raised full-year 2026 net sales growth expectations to approximately 5.5%–6.5%, it also outlined a restructuring program costing up to US$800 million and targeting around US$500...
Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.